Trial NCT05583357
Publication He Q, J. Clin. Med., 2022
Primary outcome on the report: The NAb titers against dominantly circulating VOCs at 14 and 28 days after the booster.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.